HUE054037T2 - CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra - Google Patents

CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra

Info

Publication number
HUE054037T2
HUE054037T2 HUE18797311A HUE18797311A HUE054037T2 HU E054037 T2 HUE054037 T2 HU E054037T2 HU E18797311 A HUE18797311 A HU E18797311A HU E18797311 A HUE18797311 A HU E18797311A HU E054037 T2 HUE054037 T2 HU E054037T2
Authority
HU
Hungary
Prior art keywords
methods
drug conjugates
antibody drug
activatable antibody
activatable
Prior art date
Application number
HUE18797311A
Other languages
English (en)
Inventor
Shweta Singh
Jennifer Hope Richardson
Laura Patterson Serwer
Jonathan Alexander Terrett
Susan E Morgan-Lappe
Tracy Henriques
Sherry L Ralston
Marvin Robert Leanna
Ilaria Badagnani
Sahana Bose
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of HUE054037T2 publication Critical patent/HUE054037T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
HUE18797311A 2017-10-14 2018-10-12 CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra HUE054037T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762572467P 2017-10-14 2017-10-14

Publications (1)

Publication Number Publication Date
HUE054037T2 true HUE054037T2 (hu) 2021-08-30

Family

ID=64110112

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18797311A HUE054037T2 (hu) 2017-10-14 2018-10-12 CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra

Country Status (34)

Country Link
US (3) US20190111150A1 (hu)
EP (2) EP3691692B8 (hu)
JP (2) JP7374891B2 (hu)
KR (4) KR20220045088A (hu)
CN (1) CN111278467A (hu)
AR (1) AR115178A1 (hu)
AU (1) AU2018346969A1 (hu)
BR (1) BR112020007302B1 (hu)
CA (1) CA3077730A1 (hu)
CL (1) CL2020000977A1 (hu)
CO (1) CO2020005685A2 (hu)
CR (1) CR20200206A (hu)
CY (1) CY1123968T1 (hu)
DK (1) DK3691692T3 (hu)
DO (1) DOP2023000150A (hu)
EC (1) ECSP20025198A (hu)
ES (1) ES2864013T3 (hu)
HR (1) HRP20210436T8 (hu)
HU (1) HUE054037T2 (hu)
IL (1) IL273586A (hu)
LT (1) LT3691692T (hu)
MA (1) MA50752B1 (hu)
MD (1) MD3691692T2 (hu)
MX (1) MX2020003723A (hu)
PE (1) PE20210125A1 (hu)
PL (1) PL3691692T3 (hu)
PT (1) PT3691692T (hu)
RS (1) RS61596B1 (hu)
RU (2) RU2771292C2 (hu)
SG (1) SG11202003378WA (hu)
SI (1) SI3691692T1 (hu)
TW (2) TWI780237B (hu)
UY (1) UY37931A (hu)
WO (1) WO2019075417A1 (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
BR112017023862A2 (pt) * 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
CA3179911A1 (en) * 2020-04-08 2021-10-14 Janssen Biotech, Inc. Compositions and methods for blood-brain barrier delivery
WO2021207657A1 (en) * 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
WO2024026474A1 (en) * 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001513A1 (en) 1986-08-28 1988-03-10 Teijin Limited Cytocidal antibody complex and process for its preparation
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP1919931A4 (en) 2005-08-31 2010-01-20 Univ California CELLULAR LIBRARIES OF PEPTIDE SEQUENCES (CLIPS) AND METHODS OF USE THEREOF
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
EP2570137A3 (en) * 2007-11-07 2013-08-21 Celldex Therapeutics, Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP2385955B1 (en) 2009-01-12 2020-08-12 CytomX Therapeutics, Inc. Modified antibody compositions, methods of making and using thereof
ES2725356T3 (es) * 2009-04-29 2019-09-23 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos monoclonales de ERG2 y su uso terapéutico
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
SG191977A1 (en) * 2011-02-01 2013-08-30 Genmab As Human antibodies and antibody-drug conjugates against cd74
HUE054362T2 (hu) * 2012-01-31 2021-09-28 Sbi Biotech Co Ltd Foszfolipáz D4 elleni antitest
WO2014026136A2 (en) 2012-08-10 2014-02-13 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
CN103145847B (zh) * 2013-02-05 2014-05-21 浙江大学 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
KR102535900B1 (ko) * 2013-12-25 2023-05-26 다이이찌 산쿄 가부시키가이샤 항 trop2 항체-약물 컨쥬게이트
BR112017023862A2 (pt) * 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
CN106237341B (zh) * 2016-07-12 2019-07-30 浙江大学 一种抗体偶联药物及其制备方法和应用

Also Published As

Publication number Publication date
TWI780237B (zh) 2022-10-11
PL3691692T3 (pl) 2021-07-19
KR20230004932A (ko) 2023-01-06
EP3834846A1 (en) 2021-06-16
HRP20210436T1 (hr) 2021-04-30
KR102529359B1 (ko) 2023-05-09
ECSP20025198A (es) 2020-06-30
PT3691692T (pt) 2021-03-29
TW201927815A (zh) 2019-07-16
KR20220045088A (ko) 2022-04-12
JP2020537649A (ja) 2020-12-24
WO2019075417A1 (en) 2019-04-18
AU2018346969A1 (en) 2020-04-23
MA50752B1 (fr) 2021-03-31
DK3691692T3 (da) 2021-03-22
RU2020115713A (ru) 2021-11-16
SI3691692T1 (sl) 2021-04-30
KR20230070046A (ko) 2023-05-19
BR112020007302B1 (pt) 2023-01-31
MA50752A (fr) 2020-08-12
PE20210125A1 (es) 2021-01-19
BR112020007302A2 (pt) 2020-09-29
US20190111150A1 (en) 2019-04-18
MX2020003723A (es) 2020-07-22
RS61596B1 (sr) 2021-04-29
KR20200070324A (ko) 2020-06-17
RU2771292C2 (ru) 2022-04-29
AR115178A1 (es) 2020-12-09
CO2020005685A2 (es) 2020-05-15
HRP20210436T8 (hr) 2022-01-07
EP3691692B8 (en) 2021-05-26
IL273586A (en) 2020-05-31
US20210145978A1 (en) 2021-05-20
CR20200206A (es) 2021-02-18
UY37931A (es) 2019-04-30
CN111278467A (zh) 2020-06-12
LT3691692T (lt) 2021-05-10
ES2864013T3 (es) 2021-10-13
RU2020115713A3 (hu) 2022-02-25
US20240115724A1 (en) 2024-04-11
EP3691692B1 (en) 2020-12-30
KR102385495B1 (ko) 2022-04-15
SG11202003378WA (en) 2020-05-28
MD3691692T2 (ro) 2021-05-31
CA3077730A1 (en) 2019-04-18
JP2024012366A (ja) 2024-01-30
RU2022111211A (ru) 2022-05-05
CL2020000977A1 (es) 2020-09-11
DOP2023000150A (es) 2023-08-31
TW202330039A (zh) 2023-08-01
JP7374891B2 (ja) 2023-11-07
EP3691692A1 (en) 2020-08-12
CY1123968T1 (el) 2022-05-27

Similar Documents

Publication Publication Date Title
HK1257056A1 (zh) 抗dll3抗體藥物綴合物以及使用方法
IL270921A (en) Activatable anti-PDL1 antibodies and methods of using them
ZA201900059B (en) Anti-b7-h3 antibodies and antibody drug conjugates
HK1259127A1 (zh) 吡咯並苯並二氮雜䓬抗體-藥物綴合物和使用方法
IL272703A (en) Activatable anti-CD166 antibodies and methods of using them
HK1250035A1 (zh) 抗cd 71抗體，可活化抗cd 71抗體及其使用方法
IL273586A (en) Activatable anti-cd71 antibody-drug conjugates and methods of using them
IL251938A0 (en) Antibodies against CS1 and antibody-drug conjugates
SG11201607746QA (en) Anti-egfr antibodies and antibody drug conjugates
IL282856A (en) Activatable anti-CD166 antibodies and methods of using them
EP3294810A4 (en) Silicon based drug conjugates and methods of using same
EP3625253A4 (en) ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE
IL272920A (en) EGFR Antibody Drug Conjugates (ADC) and Their Uses
IL273048A (en) Melanin antibodies and their uses
IL278225A (en) Anti SEZ6 antibody drug conjugates and methods of use